Press coverage about Immune Pharmaceuticals (NASDAQ:IMNP) has trended somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Immune Pharmaceuticals earned a news impact score of 0.09 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.0901329154729 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Immune Pharmaceuticals Inc. (IMNP) Given $3 Consensus Target … – ExpertGazette (expertgazette.com)
- Hot Stock That Must Be in Your Portfolio – Immune Pharmaceuticals Inc (NASDAQ: IMNP) – Alpha Beta Stock (alphabetastock.com)
- Sizzling Stock Alert: Immune Pharmaceuticals Inc. (IMNP) – Emn News (emnnews.com)
- Analysts’ Activity to Watch: Immune Pharmaceuticals Inc. (IMNP … – ExpertGazette (expertgazette.com)
- Immune Pharmaceuticals Inc. (NASDAQ:IMNP) – Investors are Unsure How to React (Brief Analysis) – Nasdaq Journal (press release) (nasdaqjournal.com)
Separately, Maxim Group initiated coverage on shares of Immune Pharmaceuticals in a research note on Friday, January 5th. They issued a “buy” rating and a $3.00 price objective for the company.
Immune Pharmaceuticals (NASDAQ:IMNP) last posted its quarterly earnings data on Wednesday, November 15th. The biopharmaceutical company reported ($0.34) EPS for the quarter.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Immune Pharmaceuticals (IMNP) Share Price” was first posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://baseballnewssource.com/markets/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-immune-pharmaceuticals-imnp-share-price/1848580.html.
Immune Pharmaceuticals Company Profile
Immune Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company’s segment is acquiring, developing and commercializing prescription drug products.
Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.